Systematic review and meta-analysis of humoral immunity proteins and mortality in sepsis
Authors:
Open Access
- 22 December 2025
- journal article
- review article
- Published by Springer Nature in Critical Care
- Vol. 30 (1)
Abstract
Purpose: Humoral immunity proteins—immunoglobulins, complement proteins, and antimicrobial peptides—have key antimicrobial and immunomodulatory functions in sepsis. We hypothesised that their circulating levels are lower in non-survivors, potentially resulting in impaired bacterial clearance and persistent or recurrent infections. Methods: We performed a systematic review and meta-analysis evaluating differences in humoral immunity proteins between survivors and non-survivors in adult patients with sepsis. PubMed and Embase were searched without date restrictions. Random-effects meta-analyses were used to estimate pooled standardised mean differences (SMD) with 95% confidence intervals (CI). Sensitivity analyses included data from the MIMIC-IV ICU database, and further supplemented by three proteomic studies. Results: Thirty-six studies including 6,330 patients were analysed. Thirteen reported on immunoglobulins, 17 on complement proteins, and 7 on the antimicrobial peptide heparin-binding protein (HBP). Survivors had significantly higher levels of complement proteins C3 (SMD 0.53 [0.07–0.99]) and C4 (SMD 0.51 [0.09–0.94]) compared to non-survivors. Conversely, C4a (SMD − 1.17 [–1.77 to − 0.56]) and IgA (SMD − 0.21 [–0.39 to − 0.03]) were significantly lower in survivors. No differences were found for IgG (SMD 0.00 [–0.18 to 0.18]), IgM (SMD − 0.02 [–0.13 to 0.08]), C5, C5a, or HBP. Sensitivity analyses using MIMIC-IV ( n = 2,452) and proteomic datasets supported these findings. Proteomic data revealed early depletion of classical complement components (C3, C4B) and regulatory proteins in non-survivors. Conclusion: Sepsis non-survivors exhibit lower C3 and C4 levels and higher C4a, consistent with complement activation and/or depletion. Complement proteins may serve as potential biomarkers and therapeutic targets in sepsis.Keywords
Funding Information
- Medical Research Council (W030489/1)
- National Institute for Health and Care Research
This publication has 80 references indexed in Scilit:
- Complement system activation: bridging physiology, pathophysiology, and therapyIntensive Care Medicine, 2024
- Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for SepsisJAMA, 2019
- Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study)Intensive Care Medicine, 2018
- Serum IgG levels and mortality in patients with severe sepsis and septic shockMedizinische Klinik - Intensivmedizin und Notfallmedizin, 2016
- The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)JAMA, 2016
- Influence of the serum levels of immunoglobulins on clinical outcomes in medical intensive-care patientsMedizinische Klinik - Intensivmedizin und Notfallmedizin, 2015
- Increased plasma levels of heparin-binding protein in patients with shock: a prospective, cohort studyInflammation Research, 2011
- Bactericidal/permeability-increasing protein (BPI) in sepsis correlates with the severity of sepsis and the outcomeIntensive Care Medicine, 2000
- Chronological changes in the complement system in sepsisSurgery Today, 1996
- Complement Activation and Polymorphonuclear Neutrophil Leukocyte Elastase in SepsisArchives of Surgery, 1992